Acumen Pharmaceuticals, Inc. (ABOS) |
4.21 -0.08 (-1.86%)
|
09-27 16:00 |
Open: |
4.29 |
Pre. Close: |
4.29 |
High:
|
4.34 |
Low:
|
4.19 |
Volume:
|
190,655 |
Market Cap:
|
244(M) |
|
|
Technical analysis |
as of: 2023-09-27 4:17:26 PM |
Short-term rate:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Mid-term rate:
|
|
Target: |
Six months: 6.59 One year: 7.7  |
Support: |
Support1: 4.11 Support2: 3.41 |
Resistance: |
Resistance1: 5.64 Resistance2: 6.59  |
Pivot: |
5.06  |
Moving Average: |
MA(5): 4.38 MA(20): 5.32 
MA(100): 5.89 MA(250): 5.78  |
MACD: |
MACD(12,26): -0.6 Signal(9): -0.5  |
Stochastic oscillator: |
%K(14,3): 7 %D(3): 5.3  |
RSI: |
RSI(14): 19.6  |
52-week: |
High: 11.31 Low: 3.51 |
Average Vol(K): |
3-Month: 1,195 (K) 10-Days: 322 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABOS ] has closed above bottom band by 10.0%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
4.42 - 4.45 |
4.45 - 4.47 |
Low:
|
4.15 - 4.19 |
4.19 - 4.22 |
Close:
|
4.23 - 4.29 |
4.29 - 4.34 |
|
Company Description |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. |
Headline News |
Tue, 19 Sep 2023 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Mon, 18 Sep 2023 Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This ... - Nasdaq
Sun, 17 Sep 2023 Acumen Pharmaceuticals, Inc.'s (NASDAQ:ABOS) largest shareholders are private equity firms with 38% ownership, individual investors own 26% - Yahoo Finance
Wed, 06 Sep 2023 Acumen Pharmaceuticals to Participate in the H.C. - GlobeNewswire
Tue, 08 Aug 2023 Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights - Yahoo Finance
Fri, 28 Jul 2023 Does Acumen Pharmaceuticals Inc (ABOS) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
58 (M) |
Shares Float |
27 (M) |
% Held by Insiders
|
7.8 (%) |
% Held by Institutions
|
51.7 (%) |
Shares Short
|
1,750 (K) |
Shares Short P.Month
|
1,550 (K) |
Stock Financials |
EPS
|
-1.06 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
4.11 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
0 |
Return on Assets (ttm)
|
-16.8 |
Return on Equity (ttm)
|
-24.8 |
Qtrly Rev. Growth
|
0 |
Gross Profit (p.s.)
|
-0.56 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
-0.91 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-42 (M) |
Levered Free Cash Flow
|
-28 (M) |
Stock Valuations |
PE Ratio
|
-3.98 |
PEG Ratio
|
-0.5 |
Price to Book value
|
1.02 |
Price to Sales
|
0 |
Price to Cash Flow
|
-5.77 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|